摘要
目的观察奈达铂联合国产替吉奥一线治疗晚期胃癌的近期疗效及安全性。方法 64例进展期胃癌患者随机分为治疗组和对照组,各32例。治疗组方案:奈达铂80 mg·m^(-2),静脉滴注,第1天;替吉奥40 mg·m^(-2),分2次饭后口服,第1-14天。对照组方案:顺铂60 mg·m^(-2),静脉滴注,第1-3天;LV 200 mg·m^(-2),静脉滴注,第1天;5-FU 1000 mg·m^(-2),持续微量泵滴入46小时;3周为1周期。每2个周期评价一次,至少完成2周期后评价两组的有效率、不良反应、疾病进展时间(TTP)和总生存时间(OS)。结果治疗组和对照组患者TTP分别为6.81个月和5.13个月(P=0.041);OS分别为10.81个月和8.06个月(P=0.038),差异均有统计学意义。治疗组和对照组的有效率(CR+PR)分别为56.3%和28.1%,差异有统计学意义(P<0.05),治疗组临床获益率(CR+PR+SD)为87.5%,优于对照组的62.5%,差异有统计学意义(P<0.05)。治疗组的不良反应发生率明显低于对照组。结论奈达铂联合替吉奥治疗进展期胃癌疗效较好,不良反应轻微。
Objective To investigate the clinical efficacy and safety of S-1 combined with nedaplatin as the first-line treatment for patients with advanced gastric cancer. Methods Sixty-four patients with advanced gastric cancer were randomly divided into treatment group and control group, each with 32 cases. Patients in treatment group were administered with the dose of 40 mg·m-2 S-1 given orally twice a day from d1 to d14, plus Nedaplatin at a dose of 80 mg·m-2 by intravenous infusion on d1. Patients in the control group were treated with Cisplatin at a dose of 60 mg·m-2 by intravenous infusion from d1 to d3, plus 5-fluorouracil at a dose of 1000 mg·m-2 by continuous intravenous infusion for 46 hours and LV 200 mg·m-2 by intravenous infusion on d1. One cycle lasted for three weeks. Evaluation was carried out after every two cycles. The short-term efficacy, adverse effect, time to progress（TTP）, overall survival（OS） were compared between the two groups at least after two cycles＇ treatment. Results The TTP was 6.81 months and 5.13 months respectively in the treatment group and control group（P=0.041）, and the OS was respectively 10.81 months and 8.06 months（P=0.038）. There were significant differences in TTP and OS between the two groups. The total effective rate（CR＋PR） was respectively 56.3% and 28.1% in treatment group and control group, and there was statistically significant difference between the two groups（P〈0.05）. The clinical benefit rate（CR＋PR＋SD） was 87.5% in the treatment group, whereas was 62.5% in the control group, with significant differences（P〈0.05）. The incidence of adverse effects was obviously lower in the treatment group than those in the control group（P〈0.05）. Conclusion S-1 combined with nedaplatin had good effects but slight adverse reactions in the treatment of patients with advanced gastric cancer.
出处
《肿瘤药学》
CAS
2016年第5期379-383,共5页
Anti-Tumor Pharmacy
关键词
奈达铂
替吉奥
进展期胃癌
化疗
Nedaplatin
S-1
Advanced gastric cancer
Chemotherapy
